Beta Amyloid Peptide: Research Paper : Is COVID-19 a Perfect Storm for Parkinson's Disease?

Is COVID-19 a Perfect Storm for Parkinson's Disease?

Abstract

Three recent case reports by Méndez-Guerrero et al. [3], Cohen et al. [4], and Faber et al. [5] describe the development of acute parkinsonism following coronavirus disease 2019 (COVID-19). We discuss possible underlying cellular and molecular mechanisms, and whether COVID-19 might be associated with elevated long-term risk of Parkinson's disease (PD).

Keywords: SARS-CoV-2; alpha-synuclein; dopamine; neurodegeneration; neuroinflammation.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Conflict of interest statement

Disclaimer Statement P.B. has received commercial support as a consultant from Axial Biotherapeutics, Calico Life Sciences, CuraSen, Fujifilm-Cellular Dynamics International, Idorsia, IOS Press Partners, LifeSci Capital LLC, Lundbeck A/S, and Living Cell Technologies LTD. He received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and Axial Biotherapeutics, and is on the steering committee of the NILO-PD trial.

This article originally appeared in the "https://pubmed.ncbi.nlm.nih.gov/33158605/" and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice.